Evidence map›Paper›PMID 31308757›Full record

ArticleCancer management and research2019

Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an

Gloria Ravegnini, Giulia Sammarini, Sebastian Moran, Giovanni Calice, Valentina Indio, Milena Urbini, Annalisa Astolfi, Federica Zanotti, Maria A Pantaleo, Patrizia Hrelia and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Gloria Ravegnini *Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Giulia Sammarini *Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Sebastian MoranCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institue (Idibell), l'Hospitalet de Llobregat, Barcelona, Spain.
Giovanni CaliceLaboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Valentina IndioGiorgio Prodi Cancer Research Center, University of Bologna, Bologna, Italy.
Milena UrbiniGiorgio Prodi Cancer Research Center, University of Bologna, Bologna, Italy.
Annalisa AstolfiGiorgio Prodi Cancer Research Center, University of Bologna, Bologna, Italy.
Federica ZanottiDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Maria A PantaleoGiorgio Prodi Cancer Research Center, University of Bologna, Bologna, Italy.
Patrizia HreliaDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Sabrina AngeliniDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
University of Bologna · ITCentro di Riferimento Oncologico della Basilicata · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BYL719gastrointestinal stromal tumorsGISTPI3K inhibitortyrosine-kinase inhibitors

Identifiers

PMID31308757
PMCPMC6615718
OpenAlexW2953949345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.